Production (Stage)
Seres Therapeutics, Inc.
MCRB
$7.09
$0.040.57%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -31.22% | 73.54% | |||
| Gross Profit | 31.22% | -73.54% | |||
| SG&A Expenses | -4.61% | -1.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.55% | -1.15% | |||
| Operating Income | 5.55% | 1.15% | |||
| Income Before Tax | 309.00% | 69.36% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 309.00% | 69.36% | |||
| Earnings from Discontinued Operations | -- | -100.00% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 309.00% | -117.61% | |||
| EBIT | 5.55% | 1.15% | |||
| EBITDA | 5.73% | 0.06% | |||
| EPS Basic | 305.70% | -115.70% | |||
| Normalized Basic EPS | -1,023.07% | 103.63% | |||
| EPS Diluted | 298.28% | -116.26% | |||
| Normalized Diluted EPS | -1,021.82% | 103.63% | |||
| Average Basic Shares Outstanding | 1.61% | 12.23% | |||
| Average Diluted Shares Outstanding | 1.74% | 12.23% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||